GeNeuro SA

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…

Biotechnology

CH, Plan-les-Ouates [HQ]

Summary
Fin. Reports
Financials
Leadership & Strategy
Government, Law & Regulation
Employees
More Analysis

Earnings Call Transcripts

Earnings Call · Transcripts · Speakers

This analysis tool shows transcript versions of the official earnings calls hosted by GeNeuro SA

Could not find a transcript

Earnings Call Transcripts

Could not find a transcript

Peers Transcripts

Peers Analysis

Sorry! None of GNRO.PA's peers has listed transcripts.

SEC Reader

The document search tool might be interesting as well.
Give it a try, to quickly access SEC Filings-

10-K · 10-Q · DEF 14A · S-4

Upcoming Transcript Tools

Full Text Search - Across All Transcripts
Detail Speaker Profiles
Non-US Transcripts